Citations

Clear

13603 citation(s) found for "_, _".

The relationship between performance validity test failure, fatigue, and psychological functioning in Long COVID
Minor, Greta , Kessler, Olivia R., Fry, Laura, Huizenga, Brooke , Naini, Savana M. , Shen, Chen , Wiitala, Sophie J., Eskridge, Courtney, Holker, Erin , Logemann, Allison, Waldron, Eric J. , Whiteside, Douglas M. , Basso, Michael R. , Waldron, Eric J , Whiteside, Douglas , Johnson, Sara

Mayo Clinic

The Clinical Neuropsychologist | March 8, 2025 | Volume: 40 | Issue: 1 | Pages: 242-257

10.1080/13854046.2025.2476798 | PMID 40056074 Get It

Modulating limbic circuits in temporal lobe epilepsy: impacts on seizures, memory, mood and sleep
Křemen, Václav , Sladky, Vladimir , Mívalt, Filip , Gregg, Nicholas M. , Brinkmann, Benjamin H. , Balzekas, Irena , Marks, Victoria S. , Lundstrom, Brian N. , Cui, Jie, Alden, Eva , Fields, Julie A. , Crockett, Karla, Adolf, Jindřich , Bilderbeek, Jordan, Hermes, Dora, Miller, Kai J. , Bilderbeek, Jordan , Marks, Victoria S , Kucewicz, Michal, Lundstrom, Brian Nils , St Louis, E K , Croarkin, Paul E , Alden, Eva C, Messina, Steven, Miller, Kai Joshua, Van Gompel, Jamie, Brinkmann, Benjamin H , Kremen, Vaclav , Gregg, Nicholas M , Bilderbeek, Jordan A , Mivalt, Filip , Kucewicz, Michał T. , Cui, Jie , Louis, Erik K. St. , Croarkin, Paul E. , Joseph, Boney , Hermes, Dora , Messina, Steven A. , Gompel, Jamie J. Van , Denison, Timothy , Worrell, Gregory A.

Mayo Clinic

Brain Communications | March 7, 2025 | Volume: 7 | Issue: 2 | Pages: No page available

10.1093/braincomms/fcaf106 | PMID 40196395 Get It

Abstract Temporal lobe epilepsy is a common neurological disease characterized by recurrent seizures that often originate within limbic networks involving amygdala and hippocampus. The limbic network is involved in crucial physiologic functions involving memory, emotion and sleep. Temporal lobe epilepsy is frequently drug-resistant, and people often experience comorbidities related to memory, mood and sleep. Deep brain stimulation targeting the anterior nucleus of the thalamus (ANT-DBS) is an established therapy for temporal lobe epilepsy. However, the optimal stimulation parameters and their impact on memory, mood and sleep comorbidities remain unclear. We used an investigational brain sensing-stimulation implanted device to accurately track seizures, interictal epileptiform spikes (IES), and memory, mood and sleep comorbidities in five ambulatory subjects. Wireless streaming of limbic network local field potentials (LFPs) and subject behaviour were captured on a mobile device integrated with a cloud environment. Automated algorithms applied to the continuous LFPs were used to accurately cataloged seizures, IES and sleep-wake brain state. Memory and mood assessments were remotely administered to densely sample cognitive and behavioural response during ANT-DBS in ambulatory subjects living in their natural home environment. We evaluated the effect of continuous low-frequency and duty cycle high-frequency ANT-DBS on epileptiform activity and memory, mood and sleep comorbidities. Both low-frequency and high-frequency ANT-DBS paradigms reduced seizures. However, continuous low-frequency ANT-DBS showed greater reductions in IES, electrographic seizures and better sleep and memory outcomes. These results highlight the potential of synchronized brain sensing and dense behavioural tracking during ANT-DBS for optimizing neuromodulation therapy. While studies with larger patient numbers are needed to validate the benefits of low-frequency ANT-DBS, these findings are potentially translatable to individuals currently implanted with ANT-DBS systems.
Evaluation of Etiologic Heterogeneity for Risk of Diffuse Large B-Cell Lymphoma Subtype Defined by the Cell of Origin
Kleinstern, Geffen , Robinson, Dennis P. , Rimsza, Lisa M. , Larson, Melissa C. , King, Rebecca L. , Nowakowski, Grzegorz S. , Thompson, Carrie A. , Ansell, Stephen M. , Maurer, Matthew J. , Feldman, Andrew L. , Novak, Anne J. , Slager, Susan L , Novak, Anne J , Habermann, Thomas , Cerhan, James R , Feldman, Andrew L , Maurer, Matthew , Rimsza, Lisa M , Larson, Melissa C , Slager, Susan L. , Habermann, Thomas M. , Cerhan, James R.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | March 6, 2025 | Volume: 34 | Issue: 5 | Pages: 780-787

10.1158/1055-9965.epi-24-1610 | PMID 40047811 Get It

Abstract Background: Diffuse large B-cell lymphoma (DLBCL) is clinically heterogeneous, and gene expression profiling has identified at least two biologically distinct DLBCL subtypes defined by their cell of origin (COO): germinal center B cell (GCB) and activate B cell (ABC) or non-GCB. We evaluated a variety of putative DLBCL risk factors for etiologic heterogeneity by the COO in a clinic-based study of newly diagnosed DLBCL cases (N = 638) and frequency-matched controls (N = 2,253). Methods: The COO was determined on formalin-fixed, paraffin-embedded tumor tissue, with DLBCL classified as GCB (N = 283), non-GCB (N = 188), or undetermined/missing (N = 167; mainly because of lack of tissue). Multivariable logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI). Results: We identified heterogeneity by the COO for low socioeconomic status (SES), which was only associated with non-GCB DLBCL (OR = 1.88 for low vs. average SES; 95% CI, 1.08–3.27); alcohol use, which was only associated with GCB DLBCL (OR = 0.48 for former drinkers; 95% CI, 0.29–0.80 and OR = 0.47 for current drinkers; 95% CI, 0.32–0.71); and borderline heterogeneity for the regular use of regular/extra-strength aspirin, which was only associated with non-GCB DLBCL (OR = 0.36; 95% CI, 0.16–0.85). In contrast, there was no significant heterogeneity by the COO for family history, medical history, or other lifestyle factors. Conclusions: Although requiring confirmation, most risk factors for DLBCL did not show etiologic heterogeneity by the COO, with some notable exceptions including alcohol use, SES, and perhaps regular use of regular/extra-strength aspirin showing associations. Impact: Mechanistically, these findings suggest that most of the DLBCL risk factors evaluated here influence lymphomagenesis prior to differentiation into COO subtypes, with selected factors acting later.
Ethical Considerations for Maternal-Fetal Interventions: Innovation, Research, and Oversight
Anzabi, Michele D. , Schenone, Claudio V. , Ralston, Steven J. , Cummings, Christy L. , Schenone, Claudio

Mayo Clinic

Clinical Obstetrics & Gynecology | March 5, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/grf.0000000000000936 | PMID 40042441 Get It

Advances in prenatal diagnostics, imaging, and surgical techniques have accelerated maternal-fetal interventions (MFI), fetal care centers, and expanded options for families. Progress in this field has also raised ethical issues surrounding maternal autonomy, informed consent and decision-making, innovation versus research, equitable access, and disability and reproductive rights. We review ethical frameworks to evaluate MFIs, from innovation to research and, ideally, clinical practice. Necessary oversight and resources are summarized to promote ethical, equitable innovation and research while protecting maternal autonomy and supporting the informed consent and decision-making process. Additional implications amidst abortion restrictions are discussed, along with areas for future research.
Time-restricted eating and autosomal dominant polycystic kidney disease: a pilot, randomized clinical trial
Steele, Cortney , Ostrow, Anna, Coleman, Erin R., George, Diana, Bing, Kristen , Ramanathan, Sumana, Gregory, Adriana , Kline, Timothy L. , Thomas, Elizabeth A. , Chonchol, Michel , Nowak, Kristen L. , Nowak, Kristen L , Wang, Wei Qiang , Gitomer, Berenice Y , Thomas, Elizabeth

Mayo Clinic

Clinical Kidney Journal | March 5, 2025 | Volume: 18 | Issue: 4 | Pages: No page available

10.1093/ckj/sfaf069 | PMID 40207097 Get It

ABSTRACT Background Autosomal dominant polycystic kidney disease (ADPKD) is the most commonly inherited progressive kidney disease. Time-restricted eating (TRE) is a fasting regimen that restricts eating to a particular window (typically 8 hours/day), which could slow cyst growth based on preclinical models. Methods A 12-month, randomized, controlled, behavioral dietary intervention compared TRE with a control group given healthy eating advice without TRE (HE), without caloric restriction. Participants underwent baseline and 12-month measurements, including adherence (percentage of participants adhering to the 8-hour window; primary outcome), and MRI to determine height-adjusted total kidney volume (htTKV) and adiposity. Results Twenty-nine participants (23 females, mean standard ± deviation 48 ± 9 years) with a body mass index of 31.1±5 kg/m2 were randomized to TRE (n = 14) or HE (n = 15). Of the total participants, 71% (n = 10) of TRE and 87% (n = 13) of HE participants completed the intervention. The eating window was 9.6 ± 3.6 hours for TRE (60% achieving the 8-hour window) and 12.0 ± 2.0 for HE groups (P = .07). At month 12, both groups lost modest weight (−2.4 ± 6.4% and −3.6 ± 5.4% in the TRE and HE groups, respectively). Annual change in htTKV was 3.0 ± 8.5% and 4.6 ± 8.8% in the TRE and HE groups, respectively. Both change in weight (r = 0.67, P < .01) and change in visceral adiposity (r = 0.54, P < .01) were positively correlated with change in htTKV. Conclusion Both the TRE and HE group lost modest weight at 12 months. The targeted TRE adherence of ≥75% of participants was not achieved. Weight and adiposity loss may be more important drivers of kidney growth than the timing of eating.
eLife Assessment: Mitochondrial adenine base editing of mouse somatic tissues via adeno-associated viral delivery
Ekker, Stephen C.

Mayo Clinic

No container title available | March 4, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.105080.1.sa2 Get It

Proteomics of Extracellular Vesicles: Recent Updates, Challenges and Limitations
Singh, Mohini , Tiwari, Prashant Kumar , Kumar, Sanjay , Kumar, Sanjay , Singh, Mohini, Kashyap, Vivek Kumar

Mayo Clinic

Proteomes | March 4, 2025 | Volume: 13 | Issue: 1 | Pages: 12

10.3390/proteomes13010012 | PMID 40137841 Get It

Extracellular vesicles (EVs) are lipid-bound vesicles secreted by cells, including exosomes, microvesicles, and apoptotic bodies. Proteomic analyses of EVs, particularly in relation to cancer, reveal specific biomarkers crucial for diagnosis and therapy. However, isolation techniques such as ultracentrifugation, size-exclusion chromatography, and ultrafiltration face challenges regarding purity, contamination, and yield. Contamination from other proteins complicates downstream processing, leading to difficulties in identifying biomarkers and interpreting results. Future research will focus on refining EV characterization for diagnostic and therapeutic applications, improving proteomics tools for greater accuracy, and exploring the use of EVs in drug delivery and regenerative medicine. In this review, we provide a bird’s eye view of various challenges, starting with EV isolation methods, yield, purity, and limitations in the proteome analysis of EVs for identifying protein targets.
Brain aging shows nonlinear transitions, suggesting a midlife “critical window” for metabolic intervention
Antal, Botond , Nieuwenhuizen, Helena van , Jones, David T. , Clarke, Kieran , Weistuch, Corey , Ratai, Eva‐Maria , Dill, Ken A. , Mujica‐Parodi, Lilianne R. , Jones, David T , Dill, Ken A , Mujica-Parodi, Lilianne R , Chesebro, Anthony G. , Strey, Helmut H.

Mayo Clinic

Proceedings of the National Academy of Sciences | March 3, 2025 | Volume: 122 | Issue: 10 | Pages: No page available

10.1073/pnas.2416433122 | PMID 40030017 Get It

Understanding the key drivers of brain aging is essential for effective prevention and treatment of neurodegenerative diseases. Here, we integrate human brain and physiological data to investigate underlying mechanisms. Functional MRI analyses across four large datasets (totaling 19,300 participants) show that brain networks not only destabilize throughout the lifetime but do so along a nonlinear trajectory, with consistent temporal “landmarks” of brain aging starting in midlife (40s). Comparison of metabolic, vascular, and inflammatory biomarkers implicate dysregulated glucose homeostasis as the driver mechanism for these transitions. Correlation between the brain’s regionally heterogeneous patterns of aging and gene expression further supports these findings, selectively implicating GLUT4 (insulin-dependent glucose transporter) and APOE (lipid transport protein). Notably, MCT2 (a neuronal, but not glial, ketone transporter) emerges as a potential counteracting factor by facilitating neurons’ energy uptake independently of insulin. Consistent with these results, an interventional study of 101 participants shows that ketones exhibit robust effects in restabilizing brain networks, maximized from ages 40 to 60, suggesting a midlife “critical window” for early metabolic intervention.
Clinical progression of clonal hematopoiesis is determined by a combination of mutation timing, fitness, and clonal structure
Latorre‐Crespo, Eric , Robertson, Neil , Kosebent, E. Gozde, Uddin, Md Mesbah , Honigberg, Michael C. , Bick, Alex, Reiner, Alexander P., Fiorillo, Edoardo , Chandra, Tamir , Kirschner, Kristina , Chandra, Tamir , Robertson, Neil A , Uddin, Md M , Honigberg, Michael C , Harris, Sarah , Schumacher, Linus , Chandra, Tamir , Kirschner, Kristina , Latorre, Eric , MacGillivray, Louise , Murphy, Lee , Whitsel, Eric A , Orrù, Valeria , Marongiu, Michele , Cucca, Francesco , Deary, Ian J. , Cox, Simon R. , Marioni, Riccardo E.

Mayo Clinic

No container title available | March 3, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.02.28.640879 | PMID 40093158 Get It

Abstract Clonal hematopoiesis (CH) is characterized by expanding blood cell clones carrying somatic mutations in healthy aged individuals and is associated with various age-related diseases and all-cause mortality. While CH mutations affect diverse genes associated with myeloid malignancies, their mechanisms of expansion and disease associations remain poorly understood. We investigate the relationship between clonal fitness and clinical outcomes by integrating data from three longitudinal aging cohorts (n=713, observations=2,341). We demonstrate pathway-specific fitness advantage and clonal composition influence clonal dynamics. Further, the timing of mutation acquisition is necessary to determine the extent of clonal expansion reached during the host individual’s lifetime. We introduce MACS120, a metric combining mutation context, timing, and variant fitness to predict future clonal growth, outperforming traditional variant allele frequency measurements in predicting clinical outcomes. Our unified analytical framework enables standardized clonal dynamics inference across cohorts, advancing our ability to predict and potentially intervene in CH-related pathologies.
Sex-Specific Links Between Low Choline, Metabolic Dysfunction, and Neuropathology in Obesity: Insights from Humans and the 3xTg-AD Mouse Model of Alzheimer’s disease
Winslow, Wendy , Judd, Jessica M. , Tallino, Savannah , Roust, Lori R., Filippis, Eleanna De , Brown, Brenna, Velazquez, Ramon, Katsanos, Christos S. , Velazquez, Ramon

Mayo Clinic

No container title available | March 1, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.02.24.639990 | PMID 40060610 Get It

Abstract The growing prevalence of obesity, a risk factor for disorders such as Alzheimer’s Disease (AD), raises concerns about the effects on cognitive health. AD currently impacts 6.9 million Americans aged 65 and older and is characterized by the presence of amyloid beta (Aβ) plaques, neurofibrillary tau tangles, and neuroinflammation, all of which contribute to cognitive impairment. Insulin resistance, common in both obesity and AD, disrupts brain glucose metabolism and accelerates neurodegeneration. Understanding the factors that link these conditions could lead to new strategies for combating disease. Notably, the B-like vitamin choline is necessary for fat metabolism and has been shown to help reduce obesity incidence. However, ∼90% of Americans are deficient, and decreases in this nutrient have been associated with cognitive decline. Here, we examined circulating choline levels, inflammation, and metabolic dysfunction in human participants with obesity (BMI > 30) compared to normal BMIs (18.5–24.9), as well as in 3xTg-AD mice, an AD model, fed a choline-deficient diet throughout adulthood. Our results revealed that obese participants exhibited significantly lower circulating choline levels compared to those with a healthy BMI. Lower choline levels correlated with higher %Body fat and increased markers of insulin resistance. Elevated inflammatory cytokines in obese participants were also seen in 3xTg-AD mice on a choline-deficient diet, which exhibited significant weight gain and metabolic dysfunction. AD-like pathology was also exacerbated in choline deficient 3xTg-AD mice. These findings underscore the relationship between low choline levels, obesity, insulin resistance, and cognitive decline risk. Adequate choline intake may mitigate the risk of obesity, potentially preventing cognitive decline and associated diseases. Highlights Obesity is linked to increased insulin resistance (IR) and systemic inflammation, both of which are recognized risk factors for Alzheimer’s disease (AD). Women exhibit lower circulating choline levels compared to men, and obese individuals display significantly lower choline levels than those with a healthy BMI. Lower circulating choline levels are linked to a higher body fat percentage, increased markers of IR and liver dysfunction, as well as heightened systemic inflammation. 3xTg-AD mice on a choline-deficient diet experience considerable weight gain, metabolic dysfunction, heightened systemic inflammation, and AD-like pathology, resembling the conditions observed in obese human participants.